- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NASCACELL TECHNOLOGIES Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOVANT | 31,670 | +20,46 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| QIAGEN | 29,275 | -1,48 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 109,74 | +0,21 % | Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 35,870 | -0,03 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| EVOTEC | 4,776 | +0,76 % | Evotec zapft den Kapitalmarkt an | Evotec platziert Wandelanleihen über 116,1 Mio. EUR und finanziert damit das Transformationsprogramm "Project Horizon". Die Evotec SE hat sich frisches Kapital über den Wandelanleihemarkt gesichert.... ► Artikel lesen | |
| BIONTECH | 76,10 | -0,52 % | Warum Biotech-Aktien jetzt im Umbruch sind und Zelltherapie nicht nur bei BioNTech, Morphosys und Co. ein Thema ist. | ||
| KEROS THERAPEUTICS | 9,910 | 0,00 % | Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent First Quarter 2026 Financial Results | LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| RELAY THERAPEUTICS | 11,870 | -1,66 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies | Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported... ► Artikel lesen | |
| BICARA THERAPEUTICS | 20,050 | +0,10 % | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | ||
| VERADERMICS | 99,75 | 0,00 % | Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering | NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated ("Veradermics"), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics... ► Artikel lesen | |
| PROTAGONIST THERAPEUTICS | 99,03 | +0,67 % | Hedge Fund and Insider Trading News: Bill Ackman, Seth Klarman, David Einhorn, Michael Burry, Perbak Capital Partners, Charter Communications Inc (CHTR), Protagonist Therapeutics Inc (PTGX), and More | ||
| CG ONCOLOGY | 64,42 | +1,77 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| CENTURY THERAPEUTICS | 2,120 | 0,00 % | Century Therapeutics GAAP EPS of -$0.11 beats by $0.06 | ||
| PRAXIS PRECISION MEDICINES | 326,65 | +1,88 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| TECTONIC THERAPEUTIC | 27,210 | -0,29 % | Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights | TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027TX2100 advanced into Phase 1a healthy volunteer clinical trial... ► Artikel lesen |
Das Unternehmen NASCACELL TECHNOLOGIES AG kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NASCACELL TECHNOLOGIES AG finden Sie auf Wallstreet Online.